Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine infusion for symptom improvement in severe borderline personality disorder
2024-514361-19-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ketamine in borderline personality disorder (BPD), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary: Change in BPD symptom intensity (BSL-23) from baseline to Day 9. Planned start Oct 2024; status: authorised.
02
Drugs
ketamine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2024-514361-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514361-19-00.